244 related articles for article (PubMed ID: 11735676)
1. Cost effectiveness of treatment options in advanced breast cancer in the UK.
Brown RE; Hutton J; Burrell A
Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
3. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
Launois R; Reboul-Marty J; Henry B; Bonneterre J
Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
[TBL] [Abstract][Full Text] [Related]
4. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Verma S; Ilersich AL
Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
[TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Benedict A; Cameron DA; Corson H; Jones SE
Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Lamb HM; Wiseman LR
Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
[TBL] [Abstract][Full Text] [Related]
7. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Launois RJ; Reboul-Marty JM; Bonneterre J
Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Brown RE; Hutton J
Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
[TBL] [Abstract][Full Text] [Related]
9. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Frías C; Cortés J; Seguí MÁ; Oyagüez I; Casado MÁ
Clin Transl Oncol; 2010 Oct; 12(10):692-700. PubMed ID: 20947484
[TBL] [Abstract][Full Text] [Related]
11. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of taxane therapy.
Yee GC
Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S11-5. PubMed ID: 9435927
[TBL] [Abstract][Full Text] [Related]
13. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
[TBL] [Abstract][Full Text] [Related]
14. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
Dranitsaris G; Elia-Pacitti J; Cottrell W
Pharmacoeconomics; 2004; 22(6):375-87. PubMed ID: 15099123
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Webber-Foster R; Kvizhinadze G; Rivalland G; Blakely T
Pharmacoeconomics; 2014 Jul; 32(7):707-24. PubMed ID: 24859241
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and docetaxel. Innovation, but at what cost?
Lønning PE
Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
[No Abstract] [Full Text] [Related]
17. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer.
Hutton J; Brown R; Borowitz M; Abrams K; Rothman M; Shakespeare A
Pharmacoeconomics; 1996; 9 Suppl 2():8-22. PubMed ID: 10163967
[TBL] [Abstract][Full Text] [Related]
18. Cost utility in second-line metastatic breast cancer.
Berdeaux G; Hurteloup P
Pharmacoeconomics; 1997 May; 11(5):492-7. PubMed ID: 10168037
[No Abstract] [Full Text] [Related]
19. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
Ibrahim NK; Sahin AA; Dubrow RA; Lynch PM; Boehnke-Michaud L; Valero V; Buzdar AU; Hortobagyi GN
Lancet; 2000 Jan; 355(9200):281-3. PubMed ID: 10675076
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]